Panacea Biotec Completes Phase III Enrollment for India's First Indigenous Dengue Vaccine
Market
C
CNBC TV18•07-01-2026, 19:57
Panacea Biotec Completes Phase III Enrollment for India's First Indigenous Dengue Vaccine
- •Panacea Biotec completed Phase III enrolment for its tetravalent dengue vaccine candidate, DengiAll®.
- •10,335 participants across India enrolled in collaboration with the Indian Council of Medical Research (ICMR).
- •Participants will be monitored for two years to evaluate the vaccine's efficacy and immunogenicity.
- •DengiAll® aims to be India's first indigenous single-shot dengue vaccine, expected by 2027, pending approvals.
- •Panacea Biotec shares closed 4.56% higher on NSE at ₹383 on January 7.
Why It Matters: Panacea Biotec's indigenous dengue vaccine, DengiAll®, moves closer to market with Phase III completion.
✦
More like this
Loading more articles...
